- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- FDA advisory panel to consider OTC status of NSAIDs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Reports: ESI may start 'price war' over new hepatitis C drugs
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for multiple sclerosis made by Biogen Idec, the agency said Wednesday.
The FDA announced the approval of Tecfidera (dimethyl fumarate) capsules for adults with relapsing forms of MS.
"No drug provides a cure for multiple sclerosis, so it is important to have a variety of treatment options available for patients," FDA Division of Neurology Products director Russell Katz said. "Multiple Sclerosis can impair movement, sensation and thinking and have a profound impact on a person's quality of life."